PLoS ONE (Jan 2019)

A proteomic clock for malignant gliomas: The role of the environment in tumorigenesis at the presymptomatic stage.

  • Le Zheng,
  • Yan Zhang,
  • Shiying Hao,
  • Lin Chen,
  • Zhen Sun,
  • Chi Yan,
  • John C Whitin,
  • Taichang Jang,
  • Milton Merchant,
  • Doff B McElhinney,
  • Karl G Sylvester,
  • Harvey J Cohen,
  • Lawrence Recht,
  • Xiaoming Yao,
  • Xuefeng B Ling

DOI
https://doi.org/10.1371/journal.pone.0223558
Journal volume & issue
Vol. 14, no. 10
p. e0223558

Abstract

Read online

Malignant gliomas remain incurable with a poor prognosis despite of aggressive treatment. We have been studying the development of brain tumors in a glioma rat model, where rats develop brain tumors after prenatal exposure to ethylnitrosourea (ENU), and there is a sizable interval between when the first pathological changes are noted and tumors become detectable with MRI. Our aim to define a molecular timeline through proteomic profiling of the cerebrospinal fluid (CSF) such that brain tumor commitment can be revealed earlier than at the presymptomatic stage. A comparative proteomic approach was applied to profile CSF collected serially either before, at and after the time MRI becomes positive. Elastic net (EN) based models were developed to infer the timeline of normal or tumor development respectively, mirroring a chronology of precisely timed, "clocked", adaptations. These CSF changes were later quantified by longitudinal entropy analyses of the EN predictive metric. False discovery rates (FDR) were computed to control the expected proportion of the EN models that are due to multiple hypothesis testing. Our ENU rat brain tumor dating EN model indicated that protein content in CSF is programmed even before tumor MRI detection. The findings of the precisely timed CSF tumor microenvironment changes at presymptomatic stages, deviation from the normal development timeline, may provide the groundwork for the understanding of adaptation of the brain environment in tumorigenesis to devise effective brain tumor management strategies.